J&J’s oncology forecast aligns with GlobalData’s analyst consensus, which projects $49 billion in global sales by 2030.
The company has been bolstering its pipeline through targeted deals, including the December 2025 acquisition of Halda Therapeutics for $3.05 billion in cash. Halda’s lead asset, HLD-0915, now in Phase II, could strengthen J&J’s long-term position in prostate cancer.
J&J’s CEO said the company still seeks “small acquisitions” to identify early-stage assets with potential for major sales when supported by J&J’s scale, signaling continued targeted dealmaking.
Given the CEO’s evidence and recent deal activity, J&J’s optimistic oncology portfolio forecast appears reasonable.
Subscribe for daily updates on healthcare industry trends from the JP Morgan Healthcare Conference 2026 and to receive a comprehensive post-conference report.
Originally published by Pharmaceutical Technology, a GlobalData-owned brand.
Leave a Reply